Aberrant expression of CD13 and stem cell markers in CD133-induced liver cancer in mice.

The purpose of the study is to identify the Cancer Stem Cells (CSCs) and to determine their expression profiles in different pathological stages of liver cancer by using multiple markers Methods: In this study, the expression profiles of CD133 and CD13, along with those of stem cell markers Oct4 and SOX2, were analyzed using immunohistochemistry and immunoblotting to clarify the character of CSCs in different stages of liver cancer. CD133 liver cancer cells were injected into mice, and the tissues were processed for histology. The histological data revealed the progression of liver cancer. Immunohistochemical analysis showed the strong expression of CD133 in metastatic cancer. In contrast, the expression of CD13 in both primary and metastatic liver cancer was found to be very strong. Interestingly, the expression levels of Oct4 and SOX2 were found to be upregulated in primary tumors, but, in the metastatic stage, their expression was downregulated. The immunoblot analysis also confirmed the same result. Our findings demonstrate that tumor-suppressor proteins Oct4 and SOX2 have a prominent expression profile in the primary stage of cancer, but, in the metastatic stage, their expression is downregulated, leading to the failure to prevent metastatic cancer.